Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Gross Profit: 2011-2025

Historic Gross Profit for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to $6,740.

  • Capricor Therapeutics' Gross Profit fell 99.70% to $6,740 in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year increase of 9.96%. This contributed to the annual value of $40.0 million for FY2024, which is 58.87% up from last year.
  • As of Q3 2025, Capricor Therapeutics' Gross Profit stood at $6,740, which was down 46.02% from $12,485 recorded in Q2 2025.
  • Capricor Therapeutics' Gross Profit's 5-year high stood at $28.9 million during Q4 2024, with a 5-year trough of $6,740 in Q3 2025.
  • Its 3-year average for Gross Profit is $7.0 million, with a median of $3.9 million in 2023.
  • As far as peak fluctuations go, Capricor Therapeutics' Gross Profit soared by 2,077.36% in 2021, and later tumbled by 99.70% in 2025.
  • Quarterly analysis of 5 years shows Capricor Therapeutics' Gross Profit stood at $181,039 in 2021, then surged by 430.22% to $959,903 in 2022, then soared by 1,159.30% to $12.1 million in 2023, then skyrocketed by 138.75% to $28.9 million in 2024, then plummeted by 99.70% to $6,740 in 2025.
  • Its Gross Profit was $6,740 in Q3 2025, compared to $12,485 in Q2 2025 and $28.9 million in Q4 2024.